Sevelamer Versus Calcium Carbonate in Incident Hemodialysis Patients: Results of an Open-Label 24-Month Randomized Clinical TrialBiagio Di Iorio, Antonio Bellasi, Vincenzo Bellizzi et al.|American Journal of Kidney Diseases|2013Cited by 177
Sevelamer is cost effective versus calcium carbonate for the first-line treatment of hyperphosphatemia in new patients to hemodialysis: a patient-level economic evaluation of the INDEPENDENT-HD studyMatteo Ruggeri, Biagio Di Iorio, Antonio Bellasi et al.|Journal of Nephrology|2014Cited by 18